Research Article
Efficacy and Safety of Methylprednisolone Combined with Azithromycin in The Treatment of Children with Refractory Mycoplasma Pneumonia
Jun-Hua Peng1,*, Jin Huang1,*,✉, Chun-Lin Li2,✉
1People’s Hospital of Laifeng County, Enshi, Hubei 445700, China. 2Department of Medical Imaging, School of Medicine, Yangtze University, Jingzhou, Hubei 434023, China.
*，These authors contributed equally. ✉，Correspondence Jin Huang, People's Hospital of Laifeng County, Enshi, Hubei 445700, China. Telephone number: 13997799229. Email: [email protected]. Chun-Lin Li, Department of Medical Imaging, School of Medicine, Yangtze University, Jingzhou, Hubei 434023, China. Email: [email protected]. Received: July 9, 2019; Accepted: November 6, 2019; Published online: June 7, 2020. Cite this paper: Jun-hua Peng, Jin Huang, Chun-lin Li. (2020) Efficacy and Safety of Methylprednisolone Combined with Azithromycin in The Treatment of Children with Refractory Mycoplasma Pneumonia. Global Journal of Microbiology, 1(1): 11-15. https://naturescholars.com/gjmic.010103. https://doi.org/10.46633/gjmic.010103. Copyright © 2020 by Scholars Publishing, LLC.
Abstract
Purpose: To investigate the efficacy of methylprednisolone combined with azithromycin in the treatment of refractory mycoplasma pneumonia in children. Methods: A total of 66 pediatric patients with refractory mycoplasma pneumonia received treatment in our hospital from May 2013 to December 2015 were selected and divided into control group and experimental group according to different treatment regimens. In addition to the same conventional symptomatic and supportive treatment, the control group was given intravenous infusion of azithromycin, and the experimental group was given methylprednisolone and azithromycin. After treatment, the efficacy of the two groups was observed. Results: After the above treatment, the efficacy of the experimental group was significantly better than that of the control group (P < 0.05); the hospital stay and body temperature returned to normal time of the experimental group were significantly lower than that of the control group (P < 0.05); CRP levels in both groups were significantly decreased, but the decrease was more significant in the experimental group, significantly lower than that of the control group (P < 0.05). Conclusion: Treatment of refractory mycoplasma pneumonia in children with methylprednisolone combined with azithromycin is safe and reliable and has the value of promotion and application.
Key words: Azithromycin, Mycoplasma pneumoniae refractory, Methylprednisolone.